GENETAL, page-23

Nothing much the Dr can do until we have the final results of the investigation from the failed production run and then PAB can start making more imformed time lines of doing another production run..

I think when we get the final draft of the TOX report things will start to heat up, this is towards the end of the year and should coincide with new dates ect and some more news on DX3....

This should give a lift to the SP and if we need to CR(very most likely without partnership/dealsannounced)then hopefully less dilution but will still be substantial dilution regardless imho...

Until then we will go further down albeit on small volume and the waiting game still ticks away..

The major pumps will come mid next year imho, pumping DX1 going to trial at the end of 2024(hopefully but still in no-mans land with definatives) and then spruiking going to trial with DX3 in 2025 with also PH 2 trials for DX1...

Until mid next year there really is nothing to see and for the risk adverse a good buying oppurtunity, for those deep in the red (like most) and are already well past their risk appetite it is a long hard wait that follows and some time before green is ever seen again....